Herceptin is a specific type of monoclonal antibody, which is generally used to treat patients who are suffering from metastatic (spread) breast cancer & gastric cancers. It is also used as a part of the chemotherapy treatment for adjuvant-treatment of lymph-node positive, HER2/neu protein positive breast-cancer. Herceptin is also acknowledged as trastuzumab and primarily administered intravenously in the cancer patients. Its dose given to the patients is assessed on the basis of patients' disease history and other physiological factors for instance weight, height and type of cancer or disease condition. Rising prevalence of gastric cancers including metastatic gastric cancer is a key factor likely to drive the growth of global herceptin biosimilar market. Moreover, new product launches along with various products in the pipeline for clinical trials, growth in technological advancements, approval of new Herceptin biosimilar drugs by key companies and growth in healthcare expenditure drive the Herceptin-Biosimilar market.
As per analysis, Global
Herceptin Biosimilar Market Report 2020 by Key Players, Types, Applications,
Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide
Spread). Some of the key companies operating in the global Herceptin
Biosimilar market include Gedeon Richter, The Instituto Vital Brazil, Amgen,
Mylan, Genor Biopharma, Celltrion, AryoGen Biopharma, Mabion and among others.
Well-organized companies focus on achieving product-approvals to maintain their
position in the global herceptin-biosimilar market. Furthermore, these
companies are focused on introducing novel products to fortify their
product-portfolio in the global herceptin-biosimilar market.
By types, Herceptin Biosimilar market can be bifurcated as tablets, capsules and others. In addition, by application, market can be bifurcated as healthcare & pharmaceutical and others. Healthcare & pharmaceutical segment is projected to exhibit substantial growth rate because of growth in healthcare infrastructure provided by hospitals for instance intensive care units (ICU) & ventilators and rise in the number of patients admitted to hospitals & clinics for treatment during the forecast period.
Increase in awareness regarding
cancer treatment, followed by growth in focus on the development of Herceptin
therapeutic biosimilars, increase in research & development (R&D)
activities and rise in incidence of cancers are some major factors, which are
responsible for growth of the Herceptin Biosimilar market. Apart from this,
strict regulations regarding the approval of Herceptin biosimilars and adverse
effect related caused by Herceptin biosimilars may impact the market.
Based on regional analysis, the
North-America is a leading region in global Herceptin Biosimilar market owing
to presence of large number of key players, rapid adoption of Herceptin
biosimilars, increase in favorable reimbursement policies, rise in government
grants & funding and high healthcare expenditure across the region. The
Europe and Asia-Pacific regions are anticipated to witness higher growth rate
due to increase in number of breast cancer, introduction of new Herceptin
biosimilars and rise in focus on the development of Herceptin therapeutic
biosimilars over the forecast period. It is predicted that future of the global
Herceptin Biosimilar market will be bright on account of increase in patient
pool and growth in advancement in healthcare industry during the forecast
period.
For More Information, Click on the Link Below:-
Global
Herceptin Biosimilar Market
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing &
Communications
+91-9015378249
Follow Us
No comments:
Post a Comment